slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 65,581-65,610
Pages 3,679
Rows per page 30
Component
65,581-65,610 of 110,355
16
The slide uses a swimmer plot (left) and a waterfall plot (right) to visualize clinical response.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
17
The slide highlights clinical efficacy data from a Phase 1b trial (PROC).Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
19
Includes trial design diagram with randomization and endpoint hierarchy.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
20
The slide uses qualitative feedback from healthcare providers and KOLs to validate market demand.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
23
The slide includes detailed footnotes explaining specific adverse events and patient outcomes.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
24
Includes footnotes comparing results to historical METEOR and CANTATA studies.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
26
The slide outlines a clinical trial protocol including randomization, interim analysis for accelerated approval, and primary/secondary endpoints.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
27
The slide uses a table to summarize key value propositions and speech bubbles to provide direct KOL validation.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
30
Data cutoff date is August 18, 2022. N=21 patients.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
31
Includes a footnote comparing results to a historical P3 study.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
33
Data shows a clear correlation between achieving MEC and better clinical outcomes in PDAC patients.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
35
Includes qualitative feedback from KOLs and healthcare providers regarding clinical utility and patient selection.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
37
Data as of 6/30/2022.Aravive | Investor Presentation Deck | 39 slides · Aravive
Pitch deck Investor relations 1 hit
01
Features a photo of a child named Albie living with LAL-D.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Situation & Context1 hit
06
The slide uses iconography to represent key statistics about rare diseases.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
08
The slide uses a visual mapping of products to indications.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Golden Circle1 hit
11
The slide uses a matrix-like layout to map drug candidates against biological targets and development status.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
12
The slide uses a biological process flow to explain the therapeutic rationale for C5 inhibition.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
13
The slide uses a timeline-like arrow to represent innovation and expansion into new indications.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
15
Includes clinical trial data (Study 301) and registry survival analysis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
16
HLR = high-level results; gMG = generalised myasthenia gravis; MG-ADL = myasthenia gravis activities of daily living; QMG = quantitative myasthenia gravis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
17
Includes three distinct data visualizations: a bar chart for median MG-ADL, a box plot for change from baseline, and a line chart for mean MG-ADL over time.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
18
Includes 'Number at risk' table below the x-axis.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
19
The slide uses a Kaplan-Meier survival curve for HSCT-TMA and market sizing metrics for CSA-AKI.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Solution & ApproachLoop · Mece Breakdown1 hit
21
Comparison of molecular weight (25 kDa vs 150 kDa) and administration method.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
22
Includes clinical trial design diagram for Part A and Part B.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
24
The slide uses a horizontal timeline-like structure to compare three drug candidates (ALXN2040, ALXN2050, ALXN2080).AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
25
Includes FDA Breakthrough Designation callout and trial design diagrams.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
27
The slide uses a pyramid to segment the market by patient need and product modality.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
28
Uses a pictograph to represent patient population segments.AstraZeneca | Investor Day Presentation Deck | 49 slides · AstraZeneca
Conference presentation Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit